Clene Reports Positive Top-line Results from its Phase 2 REPAIR Clinical Trials in Parkinson’s Disease and Multiple Sclerosis - August 05, 2021
globenewswire.com/news-rele...
neurologylive.com/view/cnm-...
"We believe the REPAIR program represents a critical breakthrough for Clene, demonstrating that catalytically active CNM-Au8 improves energy production and utilization in the brains of people with Parkinson disease and multiple sclerosis. Using a novel, noninvasive brain imaging approach, the study demonstrated that a key driver of cellular ATP [adenosine triphosphate] energy production, the ratio of NAD+/NADH, was significantly increased in the brains of patients after 3 months of daily CNM-Au8 oral administration,” Robert Glanzman, MD, FAAN, chief medical officer, Clene Nanomedicine, said in a statement.1 "Remarkably, the data also show a significant rebalancing of brain ß-ATP levels in these patients, a metabolic response to treatment that suggests improved ATP energy efficiency. Our next step will be to demonstrate that these brain energetic changes result in clinically meaningful results in patients with Parkinson disease and multiple sclerosis."